The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preferred first-line (1L) treatment for metastatic urothelial carcinoma (mUC) after prior immune checkpoint inhibitor (ICI) therapy: Results from a national survey.
 
Ali Khaki
Consulting or Advisory Role - Gilead Sciences (Inst)
Research Funding - 23andMe (Inst); Acrivon Therapeutics (Inst); Janssen Oncology (Inst); Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Janssen; Pfizer/Astellas
 
Priyanka Chablani
Honoraria - Curio Science; DAVA Oncology; GU Oncology Now
Consulting or Advisory Role - AVEO; Bayer; Exelixis; Gilead Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Incendia Pharmaceuticals AB (Inst); Johnson & Johnson/Janssen (Inst); Loxo/Lilly (Inst)
Travel, Accommodations, Expenses - DAVA Oncology
 
Karine Tawagi
Honoraria - Binacea; Cardinal Health; Curio Science; GU Oncology Now; IDEOlogy Health; OncLive/MJH Life Sciences; Signify Health
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Seagen
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - Mashup Media; Medical Education Consortium; Onc Live; Precisca
 
Petros Grivas
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Daiichi Sankyo; EMD Serono; Foundation Medicine; Fresenius Kabi; Gilead Sciences; Janssen; Merck; Pfizer; Replimune; Roche; Strata Oncology
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); QED Therapeutics (Inst)
 
Jeannie Hoffman-Censits
Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Gilead Sciences; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine; Genentech; Genentech; Sanofi; Seagen (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Gilead Sciences; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate author royalty
Travel, Accommodations, Expenses - Pfizer
 
Vadim Koshkin
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; Bristol Myers Squibb Foundation; Janssen; Loxo; Merck; MSD; Pfizer; Roche/Genentech; Tempus
Research Funding - Curium Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pfizer/Astellas (Inst); Seagen (Inst); Taiho Oncology (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Elizabeth Plimack
Consulting or Advisory Role - 23andMe; Abbvie; Adaptimmune; Astellas Pharma; AstraZeneca; Aura Biosciences; Bristol-Myers Squibb/Medarex; Eisai; EMD Serono; Merck; Pfizer; Seagen; Signatera; Synthekine
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Jonathan Rosenberg
Honoraria - MashupMD; NCCN/Pfizer; Pfizer; UpToDate
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Century Therapeutics; EMD Serono; Generate Biomedicines; Gilead Sciences; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Samsung Bioepis; Seagen; Tyra Biosciences
Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Lilly; Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Amplification of chromosome 1q23 to predict cancer outcomes (Inst); Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Seagen
(OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology
 
Peter O'Donnell
Honoraria - Abbvie; Adept Field Solutions; Advarra; American Society for Clinical Pharmacology & Therapeutics; AmerisourceBergen; Astellas Pharma; Axiom Healthcare Strategies; CLD, Inc.; Curio Science; EMD Serono; FirstWord; Gilead Sciences; Great Debates and Updates; Health Advances; ImmunityBio; Institute for Enquiring Minds; IntrinsiQ; Loxo/Lilly; MashupMD; MedLearning Group; Merck; MJH Life Sciences; Parexel International Corp; Peerview; Pfizer; Pharmavision UK; Prime Education; Research to Practice; SeaGen; Vaniam Group; Vida Ventures
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Expert Testimony - Hart Wagner LLP; O'Brien and Ryan LLP
Travel, Accommodations, Expenses - Astellas Pharma; Curio Science; Seagen
Other Relationship - Dragonfly Therapeutics; Duke University; G1 Therapeutics; Janssen; Nektar